Literature DB >> 2870

Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer.

G F Longstreth, V L Go, J R Malagelada.   

Abstract

Nocturnal pain and gastric hypersecretion are common in duodenal ulcer. Therefore, we investigated the antisecretory effects of a new H2-receptor antagonist, cimetidine, in 200-, 300- or 400-mg doses, taken orally at bedtime. The 200-mg dose did not cause a statistically significant change in nocturnal (midnight to 7 a.m.) acid output and had only a borderline effect on pH. However, the 300-mg and 400-mg doses significantly (P less than 0.001) lowered acid output and increased (P less than 0.01) intragastric pH. All doses caused substantial decreases in secretory volume output. After a 400-mg dose, half the patients remained anacidic for eight hours. Dose-related increases of drug blood levels were observed and correlated with the degree and duration of inhibition of acid output. Serum gastrin levels were unaffected. Cimetidine appears to be a potent inhibitor of nocturnal gastric secretion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 2870     DOI: 10.1056/NEJM197604082941502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A).

Authors:  M Colle; E Ruedas; J Cazenave; J Auzerie; G Basilisco; G Camboni; L Manara
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.

Authors:  G M Fullarton; G McLauchlan; A Macdonald; G P Crean; K E McColl
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

4.  Anti-ulcer therapy. Past to present.

Authors:  A Bettarello
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  The preventive effect of cimetidine on producing stress ulcer in rats.

Authors:  K Sugimachi; S Sufian; T Matsumoto; T Nakamura; K Inokuchi
Journal:  Jpn J Surg       Date:  1978-09

6.  Twice-daily cimetidine does not increase gastric bacterial flora.

Authors:  J T Bourne; R A Mountford; R E Barry
Journal:  Postgrad Med J       Date:  1984-07       Impact factor: 2.401

7.  24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine.

Authors:  R E Pounder; R H Hunt; S H Vincent; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1977-02       Impact factor: 23.059

8.  The direct excitatory effects of cimetidine on the smooth muscle of guinea pig ileum.

Authors:  S Vyas; S C Verma
Journal:  Agents Actions       Date:  1981-05

9.  Tiotidine, a new H2-receptor antagonist, is a potent inhibitor of nocturnal acid secretion in duodenal ulcer patients.

Authors:  J E Valenzuela; R B Strecker; A P Douglas
Journal:  Dig Dis Sci       Date:  1981-05       Impact factor: 3.199

Review 10.  Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.